Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APTARGROUP, INC.

(ATR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

AptarGroup : Weihai Hengyu Medical Products Presentation

07/28/2021 | 05:27pm EDT

Aptar Enters into Agreement with Weihai Hengyu Medical Products

Adding Elastomeric and Plastic Component Manufacturing Capabilities in China for Injectable Drug Delivery

July 28, 2021

Forward Looking Statements & Non-GAAP Financial Measures

This press release contains forward-looking statements, including regarding the potential acquisition of Hengyu and the anticipated effects of the acquisition. Expressions or future or conditional verbs such as "will," "would" and "expects" are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the satisfaction of the conditions to closing the acquisition; the expected benefits of the acquisition; the successful integration of Hengyu; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see Aptar's filings with the Securities and Exchange Commission, including the discussion under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Aptar's Form 10-K and Form 10-Qs. Aptar undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

2

Weihai Hengyu Transaction Rationale

"We remain committed to growing our business in Asia and to creating an even stronger local presence in the region. This strategic acquisition strengthens our position to serve high growth regional markets."

- Stephan Tanda, Aptar President and CEO

1 Source: IQVIA 2020, Internal models

  • Components and devices market for injectable drugs in China is forecasted to have double-digitgrowth1
  • Regulatory support and safety supporting trend towards high quality components
  • Vaccine development (due to COVID-19)placing further emphasis on injectables as the main delivery format
  • Aptar's strategic priority is to add capabilities and capacity in high growth markets (Asia/Elastomer Components)
  • Hengyu provides local Chinese production with close proximity to Chinese customers
  • Hengyu has over 23 years of experience developing new elastomeric and plastic component solutions for the injectable drug delivery market

3

Weihai Hengyu Profile

Weihai Hengyu

Aptar Suzhou

Aptar Guangzhou

Key supplier of elastomer & plastic components for injectable drug delivery

Location:

Weihai (Shandong), China

Proximity:

~1,000 km from Shanghai &

Suzhou

Employees:

~150

Core

Rigid Needle Shields

Products:

Plungers

Tip Caps

4

Transaction Overview

  • Purchase Price: Under the contemplated transaction, and subject to the conditions described in the press release, Aptar would acquire 80% ownership interest
  • Value: Enterprise valuation on a 100% cash and debt free basis of approximately $77 million
  • Option: Under the terms of the deal, Aptar has the option to acquire the remaining 20% after a 5-year lock up period
  • Financial Impact: The transaction is not expected to have a material impact on adjusted earnings per share in 2021 or 20221
  • Financing: Funded with cash on hand

1Adjusted earnings per share is a non-GAAP financial measure. Additional information regarding this measure is available on the Company's website at www.aptar.com on the Investor's page (click on Events & Presentations for a Reconciliation of non-GAAP Financial Measures).

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

AptarGroup Inc. published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 21:25:37 UTC.


ę Publicnow 2021
All news about APTARGROUP, INC.
09/22APTAR BEAUTY + HOME AT LUXE PACK MON : Sustainability and Digitalization
PU
09/22APTARGROUP : Aptar Pharma to Showcase Latest Injectables Solutions at 2021 PDA PFS Online ..
PU
09/13APTARGROUP : Baird Adjusts AptarGroup's Price Target to $135 from $150, Keeps Neutral Rati..
MT
09/10APTARGROUP : 2021 Capital Markets Day Presentation
PU
09/10APTARGROUP : 2021 Reconciliation of Non-GAAP Financial Measures
PU
09/09APTARGROUP : Aptar to Host Virtual Capital Markets Day
BU
09/07APTARGROUP : Aptar Mourns Death of Longtime Board Member, Dr. Joanne Smith
BU
09/07AptarGroup, Inc. Announces Demise of Joanne Smith, Member of Board of Directors
CI
09/07APTAR BEAUTY + HOME LAUNCHES PURITY : a Mono-material, Low-profile, Fully Recyclable* Sol..
PU
09/07NEXT BREATH WEBINAR : Extractables & Leachables for Injectable Formulations
PU
More news
Analyst Recommendations on APTARGROUP, INC.
More recommendations
Financials (USD)
Sales 2021 3 208 M - -
Net income 2021 272 M - -
Net Debt 2021 753 M - -
P/E ratio 2021 30,2x
Yield 2021 1,24%
Capitalization 7 982 M 7 982 M -
EV / Sales 2021 2,72x
EV / Sales 2022 2,57x
Nbr of Employees 13 000
Free-Float 92,6%
Chart APTARGROUP, INC.
Duration : Period :
AptarGroup, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APTARGROUP, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 121,01 $
Average target price 150,13 $
Spread / Average Target 24,1%
EPS Revisions
Managers and Directors
Stephan B. Tanda President, Chief Executive Officer & Director
Robert W. Kuhn Chief Financial Officer & Executive Vice President
George L. Fotiades Non-Executive Chairman
Ralf Klaus Wunderlich Independent Non-Executive Director
Giovanna Kampouri Monnas Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
APTARGROUP, INC.-11.60%7 982
BERRY GLOBAL GROUP, INC.12.12%8 524
FP CORPORATION-1.85%3 159
SCIENTEX BERHAD9.07%1 708
EPL LIMITED-0.20%1 077
PACT GROUP HOLDINGS LTD46.04%972